NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Cellogen Therapeutics

Cellogen Therapeutics

Private
NoidaHealthcare & Life Scienceshttps://cellogentherapeutics.com/

Last Round

Strategic

May 18, 2026

Est. Valuation

$33.6M

Total Funding Raised

$4.1M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Cellogen Therapeutics is a biotechnology company that develops CAR-T cell-based therapies for the treatment of cancer and metabolic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts, Usage-Based SaaS

AI Layer

Application

Keywords

CAR-T therapygene therapyCGTbispecific CAR-Tcell therapyAI drug discoveryAI biotechcancer immunotherapyhematological malignanciesCRISPRcomputational biologybeta-thalassemiasickle cell diseaseGMP manufacturinglentiviral vectors

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cellogen Therapeutics Comparables

Compare Cellogen Therapeutics with similar companies based on industry and business-model similarity.

Cellogen Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Cellogen Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicMay 18, 2026
AcceleratorDec 14, 2025
SeedJan 17, 2024

Cellogen Therapeutics Investors

Notable investors and investment history

Cellogen Therapeutics investors
InvestorRounds
Kotak Alternate Asset ManagersStrategic

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 27, 2026

    Grew 16% QoQ, from 19 to 22 employees.

  • May 18, 2026

    $2.3M round led by Kotak Alternate Asset Managers.

Cellogen Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cellogen Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cellogen Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNoida
Employee Range22
Year Founded2021
Last FundingMay 18, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.